← Back to Search

Protease Inhibitor

HIV Drug Combination for HIV

Phase 2

Waitlist Available

Research Sponsored by Merck Sharp & Dohme Corp.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients must be at least 18 years old

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will test the safety and effectiveness of combining two HIV drugs with two others to treat patients who have never before received anti-HIV therapy.

Who is the study for?

This trial is for adults over 18 with HIV who've never had anti-HIV drugs. They need a viral load of at least 5,000 copies/ml and CD4 count of minimum 50 cells/mm3. Pregnant individuals or those who have previously used antiretroviral therapy cannot participate.Check my eligibility

What is being tested?

The study tests the safety and effectiveness of a combination treatment for HIV using four drugs: Indinavir, Ritonavir, Stavudine, and Lamivudine in patients new to anti-HIV medication.See study design

What are the potential side effects?

Possible side effects may include digestive issues, changes in body fat distribution, resistance to the medications over time, liver problems like hepatitis or jaundice, and possible allergic reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Merck Sharp & Dohme Corp.Lead Sponsor

2,286 Previous Clinical Trials

4,581,814 Total Patients Enrolled

Merck Sharp & Dohme LLCLead Sponsor

3,886 Previous Clinical Trials

5,054,563 Total Patients Enrolled

Media Library

Indinavir (Protease Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT00002451 — Phase 2

Human Immunodeficiency Virus Infection Research Study Groups:

Human Immunodeficiency Virus Infection Clinical Trial 2023: Indinavir Highlights & Side Effects. Trial Name: NCT00002451 — Phase 2

Indinavir (Protease Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00002451 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any potential hazards associated with this treatment regimen?

"Although there is some evidence of safety, no proof of efficacy has been established yet. Therefore, this treatment received a rating of 2 on our organisation's 1-to-3 scale."

Answered by AI

Would participants aged under 55 be able to partake in this experiment?

"This clinical trial is open to all participants aged 18 or older. In contrast, there are 108 trials for minors and 353 studies targeting those above the age of 65."

Answered by AI

Who meets the criteria for entry into this clinical trial?

"This clinical trial is recruiting 8 individuals, aged 18 and over, with an active HIV infection. To be eligible for the study applicants must have a viral load higher than 5,000 copies/ml as well as a CD4 count of at least 50 cells/mm3."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

2024. "Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00002451.

All > Hiv Infection > Cte